The Medical Letter on Drugs and Therapeutics
FROM
ISSUE1425
ISSUE1425
September 16, 2013
Ado-Trastuzumab Emtansine (Kadcyla) for HER2-Positive Metastatic Breast Cancer
Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
Ado-Trastuzumab Emtansine (Kadcyla) for HER2-Positive Metastatic Breast Cancer
September 16, 2013 (Issue: 1425)
Ado-trastuzumab emtansine (Kadcyla – Genentech), a
human epidermal growth factor receptor 2 (HER2)-targeted
antibody and microtubule inhibitor conjugate, has
been approved by the FDA for intravenous (IV) treatment
of HER2-positive metastatic...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.